Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure.
Abstract
Chronic human heart failure is characterized by abnormalities in beta-adrenergic receptor
(betaAR) signaling, including increased levels of betaAR kinase 1 (betaARK1), which
seems critical to the pathogenesis of the disease. To determine whether inhibition
of betaARK1 is sufficient to rescue a model of severe heart failure, we mated transgenic
mice overexpressing a peptide inhibitor of betaARK1 (betaARKct) with transgenic mice
overexpressing the sarcoplasmic reticulum Ca(2+)-binding protein, calsequestrin (CSQ).
CSQ mice have a severe cardiomyopathy and markedly shortened survival (9 +/- 1 weeks).
In contrast, CSQ/betaARKct mice exhibited a significant increase in mean survival
age (15 +/- 1 weeks; P < 0.0001) and showed less cardiac dilation, and cardiac function
was significantly improved (CSQ vs. CSQ/betaARKct, left ventricular end diastolic
dimension 5.60 +/- 0.17 mm vs. 4.19 +/- 0.09 mm, P < 0.005; % fractional shortening,
15 +/- 2 vs. 36 +/- 2, P < 0.005). The enhancement of the survival rate in CSQ/betaARKct
mice was substantially potentiated by chronic treatment with the betaAR antagonist
metoprolol (CSQ/betaARKct nontreated vs. CSQ/betaARKct metoprolol treated, 15 +/-
1 weeks vs. 25 +/- 2 weeks, P < 0.0001). Thus, overexpression of the betaARKct resulted
in a marked prolongation in survival and improved cardiac function in a mouse model
of severe cardiomyopathy that can be potentiated with beta-blocker therapy. These
data demonstrate a significant synergy between an established heart-failure treatment
and the strategy of betaARK1 inhibition.
Type
Journal articleSubject
Adrenergic beta-AntagonistsAnimals
Cardiomyopathy, Dilated
Cyclic AMP-Dependent Protein Kinases
Disease Models, Animal
Mice
Mice, Transgenic
Myocardium
beta-Adrenergic Receptor Kinases
Permalink
https://hdl.handle.net/10161/7806Published Version (Please cite this version)
10.1073/pnas.091102398Publication Info
(2001). Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in
a mouse model of severe heart failure. Proc Natl Acad Sci U S A, 98(10). pp. 5809-5814. 10.1073/pnas.091102398. Retrieved from https://hdl.handle.net/10161/7806.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Robert J. Lefkowitz
The Chancellor's Distinguished Professor of Medicine
Dr. Lefkowitz’s memoir, A Funny Thing Happened on the Way to Stockholm, recounts his
early career as a cardiologist and his transition to biochemistry, which led to his
Nobel Prize win.
Robert J. Lefkowitz, M.D. is James B. Duke Professor of Medicine and Professor of
Biochemistry and Chemistry at the Duke University Medical Center. He has been an Investigator
of the
Howard Allan Rockman
Edward S. Orgain Distinguished Professor of Cardiology, in the School of Medicine
Rockman Lab: Molecular Mechanisms of Hypertrophy and Heart Failure Overall Research
Direction: The major focus of this laboratory is to understand the molecular mechanisms
of hypertrophy and heart failure. My laboratory uses a strategy that combines state
of the art molecular techniques to generate transgenic and gene targeted mouse models,
combined with sophisticated physiologic measures of in vivo cardiac function. In this
manner, candidate molecules are either selectively overexp
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info